Literature DB >> 19491856

Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.

Cynthia H Seow1, Joanne M Stempak, Wei Xu, Hui Lan, Anne M Griffiths, Gordon R Greenberg, A Hillary Steinhart, Nir Dotan, Mark S Silverberg.   

Abstract

OBJECTIVES: We sought to evaluate whether two novel immunoglobulin A (IgA) cell wall polysaccharide antibodies, anti-laminarin (anti-L) and anti-chitin (anti-C), aid in the diagnosis and phenotype differentiation of Crohn's disease (CD) and ulcerative colitis (UC).
METHODS: A cohort of 818 individuals with inflammatory bowel disease (IBD; 517 CD and 301 UC) from two IBD tertiary referral centers, with median ages of 33 and 39 years, respectively, and disease duration of 8.9 years, were phenotyped using the Montreal classification, and analyzed for seven anti-glycan antibodies (gASCA (anti-Saccharomyces cerevisiae) IgG, gASCA IgA, anti-chitobioside (GlcNAc(beta1,4)GlcNAc(beta)), anti-laminaribioside (Glc(beta1,3)Glb(beta)), anti-mannobioside (Man(alpha1,3)Man(alpha)), anti-L, and anti-C) and perinuclear atypical neutrophil cytoplasmic antibodies (pANCA).
RESULTS: In the CD patient population, 73% were positive for >/=1 anti-glycan antibody. All glycan markers were specific for CD (85.4-97.7%) and more prevalent in CD vs. UC (P<0.0015). gASCA IgG and IgA best differentiated CD from UC followed by anti-L (area under the curve 0.818, 0.815, and 0.702, respectively). The addition of anti-L and anti-C to gASCA IgG and pANCA improved discrimination between CD and UC (P<0.001). Adding anti-L to gASCA and pANCA differentiated colonic CD and UC (P=0.02). An increasing number of positive antibodies was associated with early CD onset, penetrating phenotype, perianal disease, and the need for surgery (P<0.001). Anti-L was associated with ileocolonic CD (odds ratio (OR) 2.28, 95% confidence interval (CI) 1.40-3.69; P=0.001), and anti-C with penetrating (OR 2.75, 95% CI 1.50-5.04; P=0.001) and perianal disease (OR 1.95, 95% CI 1.06-3.59; P=0.03).
CONCLUSIONS: Anti-L and anti-C improve differentiation between CD and UC. Anti-L may also differentiate between isolated colonic CD and UC. Both anti-L and anti-C are independently associated with a more aggressive CD phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491856     DOI: 10.1038/ajg.2009.79

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  35 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

Review 2.  Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis.

Authors:  Amit Kaul; Susan Hutfless; Ling Liu; Theodore M Bayless; Michael R Marohn; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2012-01-31       Impact factor: 5.325

Review 3.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

Review 4.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 5.  The status of diagnostic markers for inflammatory bowel disease.

Authors:  Poonam Beniwal; Laura Harrell
Journal:  Curr Gastroenterol Rep       Date:  2010-12

6.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

Review 7.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

Review 8.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 9.  Novel biomarkers of fibrosis in Crohn's disease.

Authors:  Gianluca Pellino; Pierlorenzo Pallante; Francesco Selvaggi
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

Review 10.  Diagnostic advances in inflammatory bowel disease (imaging and laboratory).

Authors:  Maria E Moscandrew; Edward V Loftus
Journal:  Curr Gastroenterol Rep       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.